Community oncology practices need to come together as much as possible in order to respond to changes in the market, have a common voice, and to share best practices and learn from each other, said Barry Russo, chief executive officer of The Center for Cancer and Blood Disorders.
Community oncology practices need to come together as much as possible in order to respond to changes in the market, have a common voice, and to share best practices and learn from each other, said Barry Russo, chief executive officer of The Center for Cancer and Blood Disorders.
Transcript
What were the main takeaways from the Quality Cancer Care Alliance (QCCA) Winter Summit from the perspective of practice management?
The main takeaway that I walked away from the QCCA summit with is that this oncology world is getting more and more challenging. There’s so many things going on that we really need to work together as community oncology practices as much as possible in order to be able to respond to all the changes in the market, have a common voice about input we want to have in the market, and to also be able to benchmark with each other to have best practices and learn from each other.
There’s so many different things going on in so many different parts of the country, and a lot of times as a community oncology practice you feel sort of isolated, and what the QCCA program really did was give you a sense that there are a lot of other folks in the same boat with you and if we can all get on the same page and learn from each other and have a voice collectively we can make a difference.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More